Digitek

Digitek was recently recalled after medication was found to contain twice the appropriate level of the active ingredient

Digitel recalled pill (B 146)Digitek is a medication that is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication.

Because patients prescribed are already under a physician’s care for heart troubles, an incorrect dosage of this medication can be especially dangerous, creating even more cardiac instability and compounding existing problems.

Digitalis toxicity is a complication of digitalis therapy, or it may be caused by an acute ingestion of .

Do you have a claim?

If you or your loved one has suffered a serious injury or death as a result of , you may be entitled to compensation for medical expenses, loss of wages, and pain and suffering.

Please contact our Digitek lawyers today by filling out the brief questionnaire, or by calling our toll free number () for a free, no-cost, no-obligation legal evaluation of your case.

Latest News

Two lawsuits filed against makers of Digitek heart medication

Two lawsuits were recently filed against Mylan Pharmaceuticals Inc., Actavis Group, Totowa LLC, Mylan Bertek Pharmaceuticals Inc., and UDL Laboratories Inc., makers and distributors of the heart medication Digitek, also known as digoxin, on behalf of patients who took Digitek prescribed by their physicians and as a result suffered complications and died, according to the West Virginia The Record.

Read the rest of this entry »

Product liability lawsuit filed against Digitek manufacturer, distributor

Linda Weadock, on behalf of her deceased husband George Weadock, and Willie Criss and Frank Heppel, have filed a $5 million product liability against drug maker Actavis and drug distributor Mylan Pharmaceuticals, claiming their heart medication Digitek contained more than twice the active ingredient and caused serious injury or death.

Read the rest of this entry »

Caraco brand digoxin recalled; could put consumers at risk

Caraco Pharmaceutical Laboratories has alerted the Food and Drug Administration () and is issuing a consumer-level of all tablets of the generic medication Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011. The drugs are being voluntarily recalled. The tablets may differ in size and could contain more or less of the active ingredient, digoxin.

Read the rest of this entry »